Patterns of Care in Medical Oncology

Adjuvant and Neoadjuvant Therapy for ER-Positive, HER2-Negative Breast Cancer

Clinical Scenario 1: A 60-year-old woman has a 1.0-cm, ER-positive, HER2-negative, node-negative IDC (3 sentinel nodes).

Would you order an Oncotype DX assay for this patient?

Yes	82%
No	18%

*If **yes** (n = 82), which adjuvant chemotherapy, if any, would you recommend given the following Recurrence Score (RS)?*

Oncotype DX RS	AC → taxane	TC	AC	Other	None
High RS	30%	60%	6%	4%	0%
Intermediate RS	7%	62%	4%	1%	26%
Low RS	0%	4%	0%	3%	93%

Clinical Scenario 1: A 60-year-old woman has a 1.0-cm, ER-positive, HER2-negative, node-negative IDC (3 sentinel nodes). (Continued)

If **no** (n = 18), which adjuvant chemotherapy, if any, would you recommend?

No Onco*type* DX RS	AC → taxane	TC	AC	Other	None
	0%	6%	0%	6%	88%

Clinical Scenario 2: A 75-year-old woman has a 1.0-cm, ER-positive, HER2-negative, node-negative IDC (3 sentinel nodes).

Would you order an Oncotype DX assay for this patient?

Yes	46%
No	54%

*If **yes** (n = 46), which adjuvant chemotherapy, if any, would you recommend given the following RS?*

Oncotype DX RS	AC → taxane	TC	AC	Other	None
High RS	22%	63%	11%	2%	2%
Intermediate RS	3%	37%	4%	4%	52%
Low RS	0%	4%	0%	2%	94%

Clinical Scenario 2: A 75-year-old woman has a 1.0-cm, ER-positive, HER2-negative, node-negative IDC (3 sentinel nodes). (Continued)

If **no** (n = 54), which adjuvant chemotherapy, if any, would you recommend?

No Onco*type* DX RS	AC → taxane	TC	AC	Other	None
	0%	11%	0%	4%	85%

Clinical Scenario 3: A 60-year-old woman has a 3.4-cm, ER-positive, HER2-negative, node-negative IDC (3 sentinel nodes).

Would you order an Oncotype DX assay for this patient?

Yes	64%
No	36%

*If **yes** (n = 64), which adjuvant chemotherapy, if any, would you recommend given the following RS?*

Oncotype DX RS	AC ➔ taxane	TC	AC	Other	None
High RS	38%	53%	6%	2%	2%
Intermediate RS	11%	72%	6%	2%	9%
Low RS	3%	11%	2%	2%	82%

Clinical Scenario 3: A 60-year-old woman has a 3.4-cm, ER-positive, HER2-negative, node-negative IDC (3 sentinel nodes). (Continued)

If **no** (n = 36), which adjuvant chemotherapy, if any, would you recommend?

No Onco*type* DX RS	AC → taxane	TC	AC	Other	None
	33%	42%	11%	6%	8%

Research To Practice®

Clinical Scenario 4: A 75-year-old woman has a 3.4-cm, ER-positive, HER2-negative, node-negative IDC (3 sentinel nodes).

Would you order an Oncotype DX assay for this patient?

Yes	61%
No	39%

*If **yes** (n = 61), which adjuvant chemotherapy, if any, would you recommend given the following RS?*

Oncotype DX RS	AC ➔ taxane	TC	AC	Other	None
High RS	16%	69%	5%	7%	3%
Intermediate RS	3%	46%	3%	5%	43%
Low RS	2%	6%	2%	5%	85%

Clinical Scenario 4: A 75-year-old woman has a 3.4-cm, ER-positive, HER2-negative, node-negative IDC (3 sentinel nodes). (Continued)

If **no** (n = 39), which adjuvant chemotherapy, if any, would you recommend?

No Onco*type* DX RS	AC ➔ taxane	TC	AC	Other	None
	5%	41%	5%	13%	36%

Clinical Scenario 5: *A 60-year-old woman has a core biopsy of a 4-cm, ER-positive, HER2-negative, node-negative IDC (3 sentinel nodes). The patient wishes to undergo breast-conserving surgery, which will be difficult or impossible without shrinkage of the breast mass, so neoadjuvant therapy is being considered.*

Would you generally order the Oncotype DX assay for this patient?

Yes	19%
No	81%

Clinical Scenario 5: A 60-year-old woman has a core biopsy of a 4-cm, ER-positive, HER2-negative, node-negative IDC (3 sentinel nodes). The patient wishes to undergo breast-conserving surgery, which will be difficult or impossible without shrinkage of the breast mass, so neoadjuvant therapy is being considered. (Continued)

Which of the following neoadjuvant regimens, if any, would you most likely recommend for this patient?

AC ➔ taxane	55%
TC	27%
Endocrine therapy (tamoxifen or AI)	6%
AC	4%
Other	5%
None	3%

Have you ordered the Oncotype DX assay to assist with decision-making regarding neoadjuvant therapy?

Yes	28%
No	72%

Median number of assays ordered: 5

Research To Practice®

Clinical Scenario 6: *A 60-year-old woman has a 1.0-cm, ER-positive, HER2-negative IDC with 2 positive nodes.*

Would you order an Oncotype DX assay for this patient?

Yes	24%
No	76%

*If **yes** (n = 24), which adjuvant chemotherapy, if any, would you recommend given the following RS?*

Oncotype DX RS	AC → taxane	TC	AC	Other	None
High RS	38%	50%	4%	4%	4%
Intermediate RS	29%	58%	0%	0%	13%
Low RS	8%	8%	4%	4%	76%

Research To Practice®

Clinical Scenario 6: A 60-year-old woman has a 1.0-cm, ER-positive, HER2-negative IDC with 2 positive nodes. (Continued)

If **no** (n = 76), which adjuvant chemotherapy, if any, would you recommend?

No Onco*type* DX RS	AC ➔ taxane	TC	AC	Other	None
	58%	24%	7%	6%	5%

Clinical Scenario 7: A 75-year-old woman has a 1.0-cm, ER-positive, HER2-negative IDC with 2 positive nodes.

Would you order an Oncotype DX assay for this patient?

Yes	44%
No	56%

If **yes** (n = 44), which adjuvant chemotherapy, if any, would you recommend given the following RS?

Oncotype DX RS	AC → taxane	TC	AC	Other	None
High RS	25%	57%	5%	11%	2%
Intermediate RS	11%	50%	0%	9%	30%
Low RS	0%	12%	2%	2%	84%

Research To Practice®

Clinical Scenario 7: A 75-year-old woman has a 1.0-cm, ER-positive, HER2-negative IDC with 2 positive nodes. (Continued)

*If **no** (n = 56), which adjuvant chemotherapy, if any, would you recommend?*

No Onco*type* DX RS	AC → taxane	TC	AC	Other	None
	32%	34%	7%	9%	18%

Research To Practice®

Have you ordered the Oncotype DX assay for a patient with node-positive disease?

Yes	64%
No	36%

Median number of assays ordered: 5

Research To Practice®

During your career, approximately how many times have you ordered the Oncotype DX assay?

Number of times ordered	
1-20	31%
21-50	41%
51-100	16%
>100	12%

Median number of assays ordered: 40

Research To Practice®

What percent of the time did the Oncotype DX results cause you to alter your preconceived treatment recommendation?

Median   **25%**